Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab extension study after TALON in neovascular age-related macular degeneration
2020-002349-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Primary endpoint: Duration of the last interval with no disease activity up to Week 56. Started Sep 2020; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2020-002349-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002349-40.